NextCure Capital Stock from 2010 to 2024

NXTC Stock

USD 1.45 0.02 1.36%

NextCure's Capital Stock is increasing over the years with slightly volatile fluctuation. Capital Stock is expected to dwindle to about 27.5 K. Capital Stock is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. View All Fundamentals

Capital Stock

First Reported

2010-12-31

Previous Quarter

32.2 K

Current Value

27.5 K

Quarterly Volatility

8.9 K

Credit Downgrade

Yuan Drop

Covid

Check NextCure financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NextCure's main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Depreciation And Amortization of 3.2 M or Interest Expense of 6.4 M, as well as many indicators such as Price To Sales Ratio of 14.65, Dividend Yield of 0.0 or PTB Ratio of 0.29. NextCure financial statements analysis is a perfect complement when working with NextCure Valuation or Volatility modules.

Check out the analysis of NextCure Correlation against competitors.

For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.

Latest NextCure's Capital Stock Growth Pattern

Below is the plot of the Capital Stock of NextCure over the last few years. It is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. NextCure's Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NextCure's overall financial position and show how it may be relating to other accounts over time.

Capital Stock

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Capital Stock

Timeline

NextCure Capital Stock Regression Statistics

	Arithmetic Mean	17,980
	Geometric Mean	16,076
	Coefficient Of Variation	49.61
	Mean Deviation	8,376
	Median	11,000
	Standard Deviation	8,920
	Sample Variance	79.6M
	Range	21.2K
	R-Value	0.86
	Mean Square Error	22.7M
	R-Squared	0.73
	Significance	0.000044
	Slope	1,710
	Total Sum of Squares	1.1B

NextCure Capital Stock History

	2024	27.5 K
	2023	32.2 K
	2020	28 K
	2019	27 K

Other Fundumenentals of NextCure

Issuance Of Capital Stock

NextCure Capital Stock component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Long Term Debt Total	Capital Surpluse	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Capital Stock	Net Receivables
Total Assets		0.95	0.93	0.6	-0.27	-0.54	0.7	0.86	0.86	0.83	-0.18	0.95	0.83	1.0	1.0	0.81	0.83	0.83	0.83	0.21
Total Stockholder Equity	0.95		0.99	0.38	0.05	-0.59	0.66	0.93	0.93	0.9	-0.48	1.0	0.9	0.94	0.95	0.8	0.89	0.83	0.89	0.22
Net Tangible Assets	0.93	0.99		0.36	0.06	-0.66	0.66	0.95	0.95	0.95	-0.49	0.99	0.95	0.92	0.93	0.77	0.94	0.86	0.94	0.31
Current Deferred Revenue	0.6	0.38	0.36		-0.69	0.0	0.2	0.45	0.45	0.24	0.51	0.38	0.26	0.61	0.6	0.53	0.23	0.18	0.22	-0.07
Net Debt	-0.27	0.05	0.06	-0.69		-0.1	-0.29	0.12	0.12	0.07	-0.89	0.04	0.06	-0.27	-0.27	-0.07	0.07	-0.12	0.08	0.16
Retained Earnings	-0.54	-0.59	-0.66	0.0	-0.1		-0.69	-0.62	-0.62	-0.83	0.41	-0.58	-0.79	-0.53	-0.53	-0.2	-0.86	-0.72	-0.87	-0.77
Accounts Payable	0.7	0.66	0.66	0.2	-0.29	-0.69		0.52	0.52	0.74	-0.12	0.66	0.72	0.69	0.69	0.44	0.73	0.75	0.74	0.26
Long Term Debt	0.86	0.93	0.95	0.45	0.12	-0.62	0.52		1.0	0.9	-0.49	0.93	0.91	0.85	0.86	0.74	0.89	0.69	0.89	0.31
Long Term Debt Total	0.86	0.93	0.95	0.45	0.12	-0.62	0.52	1.0		0.9	-0.49	0.93	0.91	0.85	0.86	0.74	0.89	0.69	0.89	0.31
Capital Surpluse	0.83	0.9	0.95	0.24	0.07	-0.83	0.74	0.9	0.9		-0.49	0.9	1.0	0.82	0.83	0.56	1.0	0.86	0.99	0.43
Total Liab	-0.18	-0.48	-0.49	0.51	-0.89	0.41	-0.12	-0.49	-0.49	-0.49		-0.48	-0.49	-0.17	-0.18	-0.24	-0.5	-0.32	-0.5	-0.26
Net Invested Capital	0.95	1.0	0.99	0.38	0.04	-0.58	0.66	0.93	0.93	0.9	-0.48		0.9	0.94	0.95	0.8	0.89	0.83	0.89	0.22
Short Long Term Debt	0.83	0.9	0.95	0.26	0.06	-0.79	0.72	0.91	0.91	1.0	-0.49	0.9		0.82	0.82	0.57	0.99	0.85	0.98	0.38
Total Current Assets	1.0	0.94	0.92	0.61	-0.27	-0.53	0.69	0.85	0.85	0.82	-0.17	0.94	0.82		1.0	0.81	0.82	0.83	0.82	0.2
Net Working Capital	1.0	0.95	0.93	0.6	-0.27	-0.53	0.69	0.86	0.86	0.83	-0.18	0.95	0.82	1.0		0.81	0.82	0.83	0.82	0.2
Short Term Debt	0.81	0.8	0.77	0.53	-0.07	-0.2	0.44	0.74	0.74	0.56	-0.24	0.8	0.57	0.81	0.81		0.56	0.61	0.57	0.14
Common Stock	0.83	0.89	0.94	0.23	0.07	-0.86	0.73	0.89	0.89	1.0	-0.5	0.89	0.99	0.82	0.82	0.56		0.87	1.0	0.48
Property Plant Equipment	0.83	0.83	0.86	0.18	-0.12	-0.72	0.75	0.69	0.69	0.86	-0.32	0.83	0.85	0.83	0.83	0.61	0.87		0.88	0.46
Capital Stock	0.83	0.89	0.94	0.22	0.08	-0.87	0.74	0.89	0.89	0.99	-0.5	0.89	0.98	0.82	0.82	0.57	1.0	0.88		0.52
Net Receivables	0.21	0.22	0.31	-0.07	0.16	-0.77	0.26	0.31	0.31	0.43	-0.26	0.22	0.38	0.2	0.2	0.14	0.48	0.46	0.52

Click cells to compare fundamentals

About NextCure Financial Statements

NextCure stakeholders use historical fundamental indicators, such as NextCure's Capital Stock, to determine how well the company is positioned to perform in the future. Although NextCure investors may analyze each financial statement separately, they are all interrelated. For example, changes in NextCure's assets and liabilities are reflected in the revenues and expenses on NextCure's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in NextCure. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Capital Stock	32.2 K	27.5 K
Issuance Of Capital Stock	92.7 K	88.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

AVAV	AeroVironment
ELVN	Enliven Therapeutics
NFLX	Netflix

When determining whether NextCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NextCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nextcure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nextcure Stock:

How To Invest In NextCure

Details

Is NextCure Stock a good investment?

Details

What is NextCure's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of NextCure Correlation against competitors.

For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.

You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NextCure. If investors know NextCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NextCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.19)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.31)

Return On Equity

(0.55)

The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between NextCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if NextCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NextCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NextCure Capital Stock from 2010 to 2024

Latest NextCure's Capital Stock Growth Pattern

NextCure Capital Stock Regression Statistics

NextCure Capital Stock History

Other Fundumenentals of NextCure

NextCure Capital Stock component correlations

About NextCure Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY